Clinical patterns and risk factors in scleritis: a multicentric study in Colombia

de-la-Torre, Alejandra; Cabrera, Mariana; Durán, Claudia; García, Sandra; Cuevas, Miguel; Carreño, Néstor I.; Rangel, Carlos Mario; Pachón-Suárez, D; Martínez-Ceballos, María Alejandra; Mejía, María Elisa; Gómez-Rocha, Alejandra; Gómez-Durán, Camilo Andrés; Perez, Yanny; Reyes-Guanes, Juliana; Cifuentes-González, Carlos; Rojas-Carabali, William

doi:10.1007/s00417-022-05754-y

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scleritis following ocular surgery is rare, accounting for 0.3% of cases in one multi-center study [ 9 ]. Single cases and small series reported scleritis occurring after pterygium surgery, strabismus surgery [ 24 , 25 ], cataract surgery [ 26 , 27 ], and glaucoma surgery [ 28 ].…”

Section: Epidemiology and Etiology Of Scleritismentioning

confidence: 99%

Management of Scleritis in Older Adults

Butler,

Tomkins-Netzer,

Reiser

et al. 2024

Drugs Aging

View full text Add to dashboard Cite

Scleritis, an inflammatory disease of the eye affecting scleral tissue, presents unique challenges in the older adult population. Unlike their younger counterparts, older individuals manifest a distinct spectrum of the disease with different underlying etiologies, co-morbidities, altered immune function, and an increased risk of systemic side effects from medication choices. Addressing these complexities necessitates a comprehensive and multidisciplinary approach. Treatment of choice will depend on any underlying cause but generally involves non-steroidal anti-inflammatory drugs, systemic or local corticosteroids, and potentially disease-modifying anti-rheumatic drugs. Utilization of these therapeutic agents in older adults warrants careful consideration because of their potential side-effect profiles. This article critically examines the specific concerns for the use of these drugs in older patients and reviews the existing literature on their use in this specific cohort.

show abstract

Section: Epidemiology and Etiology Of Scleritismentioning

confidence: 99%

Management of Scleritis in Older Adults

Butler,

Tomkins-Netzer,

Reiser

et al. 2024

Drugs Aging

View full text Add to dashboard Cite

show abstract

Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies

Richardson,

Yoon,

Moussa

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a complex, multisystemic disease and is associated with ocular pathology in 4–12% of patients. In general, ocular disease affects Crohn’s patients more frequently than those with ulcerative colitis. Episcleritis and uveitis are the most common presentations, with episcleritis often correlating with IBD flares, whereas uveitis presents independently of IBD activity and, in some cases, may even alert clinicians to a new diagnosis of IBD. Corneal EIMs encompass a range of pathologies, such as the common and benign keratoconjunctivitis sicca (dry eye disease), which nevertheless causes significant patient discomfort, and the rarer condition of peripheral ulcerative keratitis, which warrants urgent review due to the risk of corneal perforation. Alongside EIMs, clinicians should also be aware of the iatrogenic consequences to the eye following treatment of IBD. Corticosteroids may cause cataracts, glaucoma, and—indirectly via hyperglycaemia—diabetic retinopathy. Methotrexate is irritating to ocular tissues and may cause conjunctivitis and blepharitis. Biologic medications, such as anti-TNFα agents, overlap in their use as treatment of both IBD and uveitis, and yet in some patients may also increase the risk of acute uveitis flares, as well as opportunistic, sight-threatening infections. With integrated care between gastroenterology and ophthalmology, patient outcomes can be improved by facilitating earlier detection and management of ocular disease. This narrative review summarises the ocular extraintestinal manifestations of IBD, including pathophysiology, epidemiology, and current treatment strategies.

show abstract

Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review

Morrison,

Gottman,

et al. 2024

J Rheumatol

View full text Add to dashboard Cite

ObjectiveScleritis may be idiopathic or caused by trauma, infections, or an immune-mediated condition. Our study aimed to understand the relationship between scleritis and immune-mediated disease, including presenting characteristics, serologies, and treatment course. Understanding these associations may allow clinicians to risk-stratify patients and predict their clinical and treatment course.MethodsWe conducted a retrospective chart review of 341 scleritis patients seen at a tertiary care center between January 1, 2005, and December 31, 2020. Demographics, scleritis characteristics, treatment response, recurrence, and serologic data were compared among patients with idiopathic and immune-mediated disease-associated scleritis.ResultsAmong scleritis patients seen, 145 patients (43%) had an associated immune-mediated disease, most commonly rheumatoid arthritis (39%), vasculitis (21%), or inflammatory bowel disease (14%). In most cases, the immune-mediated disease diagnosis predated the scleritis presentation (65%), though vasculitis cases were more likely to develop during or after scleritis episodes. There were no significant differences in demographics or treatment failures among scleritis patients with and without associated immune-mediated conditions. Patients with immune-mediated diseases were more likely to have a recurrence of scleritis (62% vs 49%, p=0.02).ConclusionAt our ophthalmology center, 43% of patients with scleritis had an associated immunemediated disease, and most patients with immune-mediated disease were symptomatic from this disease prior to scleritis presentation. Rheumatoid arthritis was the most commonly associated condition and typically predated the scleritis, while vasculitis was more likely diagnosed during or after the scleritis episode. Scleritis among immune-mediated disease patients is more likely to recur compared to scleritis that is idiopathic.

show abstract

Clinical patterns and risk factors in scleritis: a multicentric study in Colombia

Cited by 3 publications

References 48 publications

Management of Scleritis in Older Adults

Management of Scleritis in Older Adults

Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies

Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review

Contact Info

Product

Resources

About